A carregar...
Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
Tisagenlecleucel is a first-in-class chimeric antigen receptor (CAR) T-cell therapy approved by the US Food and Drug Administration in 2017 for relapsed/refractory (RR) acute lymphoblastic leukemia (ALL) in patients up to 25 years of age. Tisagenlecleucel is an autologous T-cell therapy that is gene...
Na minha lista:
| Publicado no: | J Adv Pract Oncol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Harborside Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6505546/ https://ncbi.nlm.nih.gov/pubmed/31086690 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|